CD3 News and Research

RSS

Micromet's blinatumomab data to be presented at two upcoming medical meetings

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that data on its lead product candidate blinatumomab will be reported at two upcoming medical meetings.

23 May 2011

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

NasVax announces the success of a Phase 2a clinical trial of a new oral immunotherapy for non-alcoholic steatohepatitis (NASH), an inflammatory disease associated with fatty liver disease and the metabolic syndrome.

21 Mar 2011

Otelixizumab Phase 3 DEFEND-1 study in new-onset autoimmune type 1 diabetes does not meet primary endpoint

Tolerx, Inc. and GlaxoSmithKline (GSK) today announced that the Phase 3 DEFEND-1 study of otelixizumab, an investigational humanized anti-CD3 monoclonal antibody, did not meet the primary efficacy endpoint of change in C-peptide at month 12 in patients with new-onset autoimmune type 1 diabetes.

11 Mar 2011

Ekomed to collaborate with Immune Network and Immunitor for further research of Immunoxel/Dzherelo

Immune Network Ltd. advises that Ukrainian company Ekomed LLC has agreed to collaborate with Immune Network and Immunitor for further clinical research of a tableted form of Ekomed's well-known immunomodulator herbal product Immunoxel/Dzherelo.

4 Mar 2011

Emergent BioSolutions awarded five grants totalling $1.2 million under QTDP Program

Emergent BioSolutions Inc. today announced that it has been awarded five separate grants under the Qualifying Therapeutic Discovery Project (QTDP) Program to support continued development of its therapeutic programs in oncology and autoimmunity. The grants, with a total value of over $1.2 million, will fund Emergent's TRU-016 Small Modular ImmunoPharmaceutical (SMIP™), DRACO anti-CD3 SMIP, X1 TNF-based SCORPION™, X2 CTLA4-based SCORPION, and T-Scorps-based SCORPION therapeutic programs.

10 Nov 2010

Karmanos Cancer Institute awarded $3M NIH grant to study triple-negative breast cancer

Scientists at the Barbara Ann Karmanos Cancer Institute in Detroit have received a nearly $3 million, five-year research project (RO1) grant from the National Institutes of Health to study a potentially ground-breaking immunotherapy treatment for women with one of the deadliest forms of breast cancer – triple-negative breast cancer. The research is exclusive to the Karmanos Cancer Institute.

19 Oct 2010

K.U.Leuven enters license agreement with Pfizer to commercialize anti-HIV drugs

K.U.Leuven announced today that on July 29th, 2010 they entered into a license agreement with Pfizer. The license agreement grants Pfizer exclusive and sublicenseable worldwide rights to further develop and commercialise K.U.Leuven's compounds with a new mechanism of action for the potential treatment of individuals infected with HIV, the virus that causes AIDS.

16 Sep 2010

Updates on Micromet's BiTE antibody development programs to be made at two medical conferences

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that updates on several of its BiTE antibody development programs will be made at two upcoming medical conferences.

21 May 2010

Recruitment of children and adults with type 1 diabetes commences in Protege Encore teplizumab trial

Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.

20 May 2010

Adults with newly diagnosed type 1 diabetes recruited for Protege Encore clinical trial

Dr. Bruce Bode announced today that he is now recruiting adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes.

18 May 2010

MedImmune to present ten abstracts at American Association for Cancer Research meeting

MedImmune today announced that ten abstracts on progress being made in various oncology programs will be presented during the Annual Meeting of the American Association for Cancer Research in Washington, DC from April 17 to 21.

17 Apr 2010

Virtuoso Digital Pathology Software: BioImagene adds Companion Algorithms for colon cancer

BioImagene, Inc., the leading provider of end-to-end digital pathology solutions, today announced the availability of Companion Algorithms™ for colon cancer in their Virtuoso™ Digital Pathology Software. BioImagene’s Companion Algorithms are unique in the digital pathology industry as they are specific to a biomarker and a tissue type. Therefore, pathologists are not faced with the challenges of customizing generic algorithms in order to make them work.

18 Mar 2010

PDL BioPharma enters into non-exclusive license agreement with Eli Lilly

PDL BioPharma, Inc. today announced that it has entered into a non-exclusive license agreement with Eli Lilly and Company under PDL's Queen et al patents with respect to teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules.

22 Dec 2009

Mechanical force switches T cell from disease-scanning to disease-fighting mode

The immune system's T cells have the unique responsibilities of being both jury and executioner. They examine other cells for signs of disease, including cancers or infections, and, if such evidence is found, rid them from the body. Precisely how T cells shift so swiftly from one role to another, however, has been a mystery.

3 Nov 2009

Rega Institute and CD3 to receive funds for new medication research for dengue treatment

The Laboratory for Virology and Experimental Chemotherapy (Rega Institute) and the "Centre for Drug Design and Discovery" (CD3) at K.U.Leuven will receive a total of 2.8 million euro from the British Wellcome Trust. - They will apply these funds to the search for possible new medication for the treatment of infections related to the 'dengue fever virus'.

26 Oct 2009

Wellcome Trust's 91M fund aims at developing new drugs related to the dengue fever virus

The Wellcome Trust spends over 600 million pounds each year to support its mission to foster and promote research with the aim to improving human and animal health. This funding supports basic research as well as technology transfer, the transfer of academic knowledge and technology to the corporate environment.

26 Oct 2009

Dose optimization data from Tolerx's Phase 2 clinical study of otelixizumab

Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.

22 Oct 2009

BioImagene announces launch of the Virtuoso digital pathology solution

BioImagene, the leading provider of innovative digital pathology solutions, today announced the availability of the next generation of its digital pathology solution, VirtuosoTM. A highlight in this version is the ability to share cases in real time, allowing pathologists to collaborate with each other to sign out cases. Virtuoso users can participate in peer reviews, perform second-opinions for difficult cases, and guide residents in the review of cases for education.

6 Oct 2009

Study shows how T cell's machinery dials down autoimmunity

A St. Jude Children's Research Hospital study shows that T cells, the body's master immune regulators, do not use simple on/off switches to govern the cellular machinery that regulates their development and function. Rather, they possess sophisticated molecular controls that enable them to adjust their function with exquisite precision. Such subtle adjustment enables T cells to modulate their development and function, including avoiding autoimmunity

12 May 2008

AIDS, an evolutionary accident?

AIDS, a fatal disease in humans, may partly be the consequence of an evolutionary accident, scientists heard at the Society for General Microbiology's 162nd meeting being held this week at the Edinburgh International Conference Centre.

1 Apr 2008